In-center hemodialysis six times per week versus three times per week

New England Journal of Medicine

Volumn 363, Issue 24, 2010, Pages 2287-2300

  Chertow, Glenn M ^a,b   Levin, Nathan W ^c   Beck, Gerald J ^d   Depner, Thomas A ^e   Eggers, Paul W ^f   Gassman, Jennifer J ^d   Gorodetskaya, Irina ^a,b   Greene, Tom ^d,g   James, Sam ^b   Larive, Brett ^d   Lindsay, Robert M ^h   Mehta, Ravindra L ⁱ   Miller, Brent ^j   Ornt, Daniel B ^k   Rajagopalan, Sanjay ^l   Rastogi, Anjay ^m   Rocco, Michael V ⁿ   Schiller, Brigitte ^a,o   Sergeyeva, Olga ^c   Schulman, Gerald ^p   Ting, George O ^a,q   Unruh, Mark L ^r   Star, Robert A ^f   Kliger, Alan S ^s,t   more..

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RENAL RESEARCH INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j WASHINGTON UNIVERSITY   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l OHIO STATE UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ WAKE FOREST UNIVERSITY   (United States)

^o University of Minnesota   (United States)

^p VANDERBILT UNIVERSITY   (United States)

^q EL CAMINO HOSPITAL   (United States)

^r UNIVERSITY OF PITTSBURGH   (United States)

^s HOSPITAL OF SAINT RAPHAEL   (United States)

^t YALE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; SERUM ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; DEPRESSION; FEMALE; HEART LEFT VENTRICLE MASS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; HYPERPHOSPHATEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINERAL METABOLISM; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR ACCESS;

EID: 78649806628     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1001593     Document Type: Article

References (39)

1. Renal Data System. USRDS 2009 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2009. (http://www.usrds.org.)
2. Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM. The treatment of chronic uremia by means of intermittent hemodialysis: a preliminary report. Trans Am Soc Artif Intern Organs 1960;6:114-22.
3. Teschan PE, Ginn HE, Bourne JR, Walker PJ, Ward JW. Quantitative neurobehavioral responses to renal failure and maintenance dialysis. Trans Am Soc Artif Intern Organs 1975;21:488-91.
4. Held PJ, Pauly MV. Competition and efficiency in the End-Stage Renal Disease program. J Health Econ 1983;2:95-118.
5. Evans RW, Manninen DL, Garrison LP Jr, et al. The quality of life of patients with end-stage renal disease. N Engl J Med 1985;312:553-9.
6. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8.
7. Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009;361:1539-47.
8. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 1993;329: 1001-6.
9. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int 1996;50:550-6.
10. McClellan WM, Soucie JM, Flanders WD. Mortality in end-stage renal disease is associated with facility-to-facility differences in adequacy of hemodialysis. J Am Soc Nephrol 1998;9:1940-7.
11. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription on patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 1981;305:1176-81.
12. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9.
13. Depner TA. Daily hemodialysis efficiency: an analysis of solute kinetics. Adv Ren Replace Ther 2001;8:227-35.
14. Suri RS, Nesrallah GE, Mainra R, et al. Daily hemodialysis: a systematic review. Clin J Am Soc Nephrol 2006;1:33-42.
15. Walsh M, Culleton B, Tonelli M, Manns B. A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 2005;67:1500-8.
16. Suri RS, Garg AX, Chertow GM, et al. Frequent Hemodialysis Network (FHN) randomized trials: study design. Kidney Int 2007;71:349-59.
17. Daugirdas JT, Greene T, Depner TA, et al. Factors that affect postdialysis rebound in serum urea concentration, including the rate of dialysis: results from the HEMO Study. J Am Soc Nephrol 2004;15:194-203.
18. Hemmelgarn BR, Manns BJ, Quan H, Ghali WA. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003;42:125-32.
19. Miskulin DC, Athienites NV, Yan G, et al. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int 2001;60:1498-510.
20. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001;33:350-7.
21. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
22. Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998;13:Suppl 6:10-4.
23. Daugirdas JT, Depner TA, Greene T, Levin NW, Chertow GM, Rocco MV. Standard Kt/V(urea): a method of calculation that includes effects of fluid removal and residual kidney clearance. Kidney Int 2010;77:637-44.
24. Bock HA, Hirt-Minkowksi P, Brünisholz M, et al. Darbepoetin alfa in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008;23:301-8.
25. DePalma JR, Pecker EA, Maxwell MH. A new automatic coil dialyzer system for 'daily' dialysis. Hemodial Int 2004;8:19-23.
26. Buoncristiani U, Quintaliani G, Cozzari M, Giombini L, Ragaiolo M. Daily dialysis: long-term clinical metabolic results. Kidney Int Suppl 1988;24:S137-S140.
27. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily hemodialysis. Am J Kidney Dis 2003;42:1020-35.
28. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005;16:2778-88.
29. Lockridge RS Jr, Spencer M, Craft V, et al. Nightly home hemodialysis: five and one-half years of experience in Lynchburg, Virginia. Hemodial Int 2004;8:61-9.
30. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007;298:1291-9.
31. Depner T, Daugirdas J, Greene T, et al. Dialysis dose and the effect of gender and body size on outcome in the HEMO study. Kidney Int 2004;65:1386-94.
32. Foley RN, Herzog CA, Collins AJ. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002;62:1784-90.
33. Neves PL, Silva AP, Bernardo I. Elderly patients in chronic hemodialysis: risk factors for left ventricular hypertrophy. Am J Kidney Dis 1997;30:224-8.
34. Szczech LA, Reddan DN, Klassen PS, et al. Interactions between dialysis-related exposures, nutritional surrogates and mortality among ESRD patients. Nephrol Dial Transplant 2003;18:1585-91.
35. Zoccali C, Benedetto FA, Mallamaci F, et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int 2004;65:1492-8.
36. Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003;64:339-49.
37. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001;12:2759-67.
38. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004;292:2343-9.
39. Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim RM. A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients. Clin J Am Soc Nephrol 2010;5:252-60.